Aortic valve replacement for end-stage aortic valve disease

Area of Science:

• Cardiology
• Cardiac Surgery
• Valvular Heart Disease

Background:

• End-stage aortic valve disease presents significant challenges, often with patients in New York Heart Association (NYHA) class IV.
• High-risk factors include cardiogenic shock and bacterial endocarditis, complicating surgical outcomes.

Purpose of the Study:

• To evaluate the outcomes of surgical intervention for end-stage aortic valve disease.
• To assess both in-hospital and long-term survival, functional status, and complication rates following aortic valve replacement.

Main Methods:

• A retrospective, longitudinal survey of 85 patients undergoing aortic valve replacement for end-stage aortic valve disease.
• Data collected included in-hospital mortality, long-term survival, New York Heart Association (NYHA) functional class, and incidence of valve-related complications.

Main Results:

• Overall in-hospital mortality was 9.4%, significantly higher in patients with endocarditis (22%).
• Long-term actuarial survival was 82% at 5 years and 74% at 10 years.
• Among late survivors, 77% improved to NYHA class I or II, with a low incidence of major valve-related complications.

Conclusions:

• Aortic valve replacement is a high-risk procedure for end-stage aortic valve disease, particularly with endocarditis.
• Favorable long-term survival, functional improvement, and manageable complication rates justify surgical intervention in this patient group.
• Despite risks, surgical intervention offers a better prognosis than conservative management for end-stage aortic valve disease.